Table 2.
Combinations of erlotinib and other tyrosine kinase inhibitors under evaluation for non-small cell lung cancer (http://www.clinicaltrials.gov)
| Agent | Description | Trial | Phase | Design |
|---|---|---|---|---|
| Pazopanib | Multiple TKIs, including VEGFRs, PDGFR, and c-kit | NCT01027598 | II | Erlotinib/pazopanib versus erlotinib/placebo in pretreated NSCLC pts |
| NCT00619424 | Ib | Pazopanib in combination with either erlotinib or pemetrexed in NSCLC pts | ||
| Dovitinib | Multiple TKIs, including FGFR and VEGFR TKI | NCT01515969 | I | Pts with advanced NSCLC who have failed any number of prior therapies |
| Tivozanib | VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFR-β TKIs | NCT01728181 | I/II | Untreated pts with advanced NSCLC |
| Tivantinib | c-Met inhibitor | NCT01580735 | II | EGFR mutation-positive NSCLC |
| NCT01244191 | III | Tivantinib and erlotinib versus erlotinib in EGFR mutationpositive NSCLC | ||
| NCT01395758 | II | Erlotinib plus ARQ 197 versus single-agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) in previously treated KRAS mutation-positive subjects with locally advanced or metastatic NSCLC | ||
| Cabozantinib | Dual c-Met/VEGFR2 inhibitor | NCT00596648 | I/II | Cabozantinib with or without erlotinib in adults with NSCLC |
| NCT01708954 | II | Erlotinib hydrochloride and cabozantinib alone or in combination as second- or third-line therapy in pts with Stage IV NSCLC | ||
| Foretinib | Dual c-Met/VEGFR2 inhibitor | NCT01068587 | I/II | Erlotinib with or without foretinib in pts with advanced NSCLC that has not responded to previous chemotherapy |
| MGCD265 | Wild type and mutant c-Met, VEGFR1, VEGFR2, VEGFR3, Ron, and Tie-2 TKIs | NCT00975767 | I/II | MGCD265 and erlotinib or docetaxel in subjects with advanced solid tumors or NSCLC |
| OSI-906 | Dual TKI of IGF-1R and IR | NCT01186861 | II | Erlotinib with or without OSI-906 in pts with nonprogression following four cycles of platinum-based chemotherapy |
| OSI-930 | Inhibitor of c-kit and KDR | NCT00603356 | I | Pts with advanced NSCLC who have failed any number of prior therapies |
Abbreviations: FGFR, fibroblast growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; IR, insulin receptor; KDR, kinase insert domain receptor; c-Met, mesenchymal–epithelial transition factor; NSCLC, non-small cell lung cancer; pts, patients; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.